文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症创伤与烧伤

预测危重症所致免疫功能障碍继发感染的分层策略:REALIST评分

A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score.
PubMed 文献 · Ann Intensive Care · 2022-08-17
一句话结论REALIST评分由mHLA-DR、未成熟中性粒细胞百分比和血清IL-10三项免疫指标构成,评分越高继发感染和死亡风险越高。

REALIST评分是REALISM研究的子研究,基于单中心前瞻性队列,纳入严重创伤、大手术或脓毒症/脓毒性休克后的危重成人,预先选定5项免疫指标,最终保留mHLA-DR、未成熟(CD10- CD16-)中性粒细胞百分比和血清IL-10水平3项。在189例队列中,D5-7评分0分者30天继发感染发生率为8%,3项异常者升至46%。校正SOFA评分和D5-7有创机械通气后,REALIST评分越高,继发感染风险(调整HR 3.22,95%CI 1.09-9.50,p=0.034)和死亡风险(p=0.001)越高。作者认为该评分可为临床提供清晰的免疫状态评估,并可能有助于设计未来免疫刺激策略试验。

要点

  • REALIST评分由mHLA-DR、未成熟(CD10- CD16-)中性粒细胞百分比和血清IL-10水平3项指标构成。
  • 在D5-7评估时,评分0分者30天继发感染发生率为8%,3项异常者升至46%。
  • 校正SOFA评分和D5-7有创机械通气后,REALIST评分越高继发感染风险越高(调整HR 3.22,95%CI 1.09-9.50,p=0.034)。
  • REALIST评分越高死亡风险也越高(10例事件(5.3%),p=0.001)。
  • 作者认为该评分是一种简单实用的分层策略,可帮助优化这类患者的照护,并可能有助于设计未来免疫刺激策略试验。

适用人群与场景

  • 严重创伤、大手术或脓毒症/脓毒性休克后收治的危重成人(单中心前瞻性队列的免疫 profiling 子研究)。

诊断标准与关键阈值

  • REALIST评分包含3项免疫参数:mHLA-DR、未成熟(CD10- CD16-)中性粒细胞百分比和血清IL-10水平,于D5-7测量。

研究设计与关键结果

  • 研究类型:单中心前瞻性队列研究的子研究,纳入严重创伤、大手术或脓毒症/脓毒性休克后的危重成人,主要结局为30天内继发感染。
  • REALIST评分最终保留3项参数:mHLA-DR、未成熟(CD10- CD16-)中性粒细胞百分比和血清IL-10水平。
  • 在感兴趣队列(n=189)中,D5-7时REALIST评分0分者30天继发感染发生率为8%,3项异常者升至46%。
  • 校正SOFA评分和D5-7有创机械通气后,REALIST评分越高与继发感染风险独立相关(42例事件(22.2%),调整HR 3.22(95%CI 1.09-9.50),p=0.034)。
  • REALIST评分越高与死亡风险独立相关(10例事件(5.3%),p=0.001)。

证据类型、等级与局限

  • 证据类型:单中心前瞻性队列研究子研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为REALIST评分是一种简单实用的分层策略,可为临床提供清晰的免疫状态评估,可能有助于优化这类患者的照护,并可能有助于设计未来免疫刺激策略试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although multiple individual immune parameters have been demonstrated to predict the occurrence of secondary infection after critical illness, significant questions remain with regards to the selection, timing and clinical utility of such immune monitoring tests.

RESEARCH QUESTION: As a sub-study of the REALISM study, the REALIST score was developed as a pragmatic approach to help clinicians better identify and stratify patients at high risk for secondary infection, using a simple set of relatively available and technically robust biomarkers.

STUDY DESIGN AND METHODS: This is a sub-study of a single-centre prospective cohort study of immune profiling in critically ill adults admitted after severe trauma, major surgery or sepsis/septic shock. For the REALIST score, five immune parameters were pre-emptively selected based on their clinical applicability and technical robustness. Predictive power of different parameters and combinations of parameters was assessed. The main outcome of interest was the occurrence of secondary infection within 30 days.

RESULTS: After excluding statistically redundant and poorly predictive parameters, three parameters remained in the REALIST score: mHLA-DR, percentage of immature (CD10- CD16-) neutrophils and serum IL-10 level. In the cohort of interest (n = 189), incidence of secondary infection at day 30 increased from 8% for patients with REALIST score of 0 to 46% in patients with a score of 3 abnormal parameters, measured ad D5-7. When adjusted for a priori identified clinical risk factors for secondary infection (SOFA score and invasive mechanical ventilation at D5-7), a higher REALIST score was independently associated with increased risk of secondary infection (42 events (22.2%), adjusted HR 3.22 (1.09-9.50), p = 0.034) and mortality (10 events (5.3%), p = 0.001).

INTERPRETATION: We derived and presented the REALIST score, a simple and pragmatic stratification strategy which provides clinicians with a clear assessment of the immune status of their patients. This new tool could help optimize care of these individuals and could contribute in designing future trials of immune stimulation strategies.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Tremblay JA, Peron F, Kreitmann L, et al. A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score. Ann Intensive Care. 2022. PMID: 35976460. doi:10.1186/s13613-022-01051-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。